

EXHIBIT 1035

U.S. Patent No. 12,491,184 - Prosecution File History
(Application No. 19/094,716)

Assembled from USPTO Patent Center records

Anagen LLC v. Veradermics, Inc.
Case PGR2026-_____ (U.S. Patent No. 12,491,184)

INDEX OF DOCUMENTS

pp. 3-3: Examiner STN/CAS search log (Nov. 12, 2024, parent examination; reused query)
pp. 4-5: Claims as filed (Mar. 28, 2025)
pp. 6-12: Information Disclosure Statement 1 (Mar. 28, 2025)
pp. 13-19: Information Disclosure Statement 2
pp. 20-30: Information Disclosure Statement 3
pp. 31-46: Information Disclosure Statement 4
pp. 47-47: Examiner Search Notes (Apr. 23, 2025)
pp. 48-52: Non-Final Office Action (Apr. 28, 2025) - nonstatutory double patenting over US 12,268,688 (sole rejection)
pp. 53-53: Notice of References Cited / PTO-892 (Apr. 28, 2025) - sole reference: US 12,268,688
pp. 54-54: Terminal Disclaimer over US 12,268,688 - approved (May 28, 2025)
pp. 55-55: Reply cover letter (May 30, 2025)
pp. 56-61: Reply to Non-Final Office Action (May 30, 2025)
pp. 62-63: Remarks accompanying Reply (May 30, 2025)
pp. 64-64: Examiner Search Notes, updated (June 10, 2025)
pp. 65-69: Information Disclosure Statement 5
pp. 70-74: Information Disclosure Statement 6
pp. 75-79: Information Disclosure Statement 7
pp. 80-80: Information Disclosure Statement 8 (examiner-initialed)
pp. 81-89: Notices of Allowability (June 18, Aug. 8, Oct. 21, 2025) + PTOL-85 - Box 6 (Reasons for Allowance) unchecked on all three
pp. 90-90: Refund request, IDS size fee (2025)
pp. 91-91: Pre-grant publication notice (July 10, 2025)
pp. 92-93: Issue Notification, US 12,491,184 (Nov. 26, 2025)

(FILE 'HOME' ENTERED AT 11:36:34 ON 12 NOV 2024)

D SET
D SEL
D CLUSTER
D CLUSTER .PHARM .PHARMACEUTICAL

FILE 'HCAPLUS' ENTERED AT 11:36:48 ON 12 NOV 2024

L1 138 SEA SPE=ON ABB=ON PLU=ON MINOXIDIL (P) ORAL (P) (HAIR OR
BALD OR BALDING OR BALDNESS)
L2 212427 SEA SPE=ON ABB=ON PLU=ON (SUSTAINED OR MODIFIED OR CONTROLLE
D OR PULSED) (7A) RELEASE
L3 4 SEA SPE=ON ABB=ON PLU=ON L1 AND L2
D L3 1-4 BIB HIT

FILE 'USPATFULL' ENTERED AT 11:42:57 ON 12 NOV 2024

L4 556 SEA SPE=ON ABB=ON PLU=ON MINOXIDIL (P) ORAL (P) (HAIR OR
BALD OR BALDING OR BALDNESS)
L5 281914 SEA SPE=ON ABB=ON PLU=ON (SUSTAINED OR MODIFIED OR CONTROLLE
D OR PULSED) (7A) RELEASE
L6 193 SEA SPE=ON ABB=ON PLU=ON L4 AND L5
L7 1 SEA SPE=ON ABB=ON PLU=ON L4 (P) L5
L8 1 SEA SPE=ON ABB=ON PLU=ON ((MINOXIDIL/TI,AB,CLM (P) ORAL/TI,A
B,CLM (P) (HAIR/TI,AB,CLM OR BALD/TI,AB,CLM OR BALDING/TI,AB,CL
M OR BALDNESS/TI,AB,CLM)) AND ((SUSTAINED/TI,AB,CLM OR
MODIFIED/TI,AB,CLM OR CONTROLLED/TI,AB,CLM OR PULSED/TI,AB,CLM)
(7A) RELEASE/TI,AB,CLM))

CLAIMS

What Is Claimed Is:

1. A method of treating hair loss, comprising orally administering to a human subject who is experiencing hair loss a modified release pharmaceutical formulation comprising about 4.5 mg of minoxidil or a molar equivalent amount of the pharmaceutically acceptable salt thereof; wherein the modified release pharmaceutical formulation provides:
 - a $C_{\max}$ of minoxidil that is about 0.25 ng/ml to about 20 ng/ml; and
 - a $T_{\max}$ of minoxidil that is about 30 to about 360 minutes.
2. The method of claim 1, wherein a blood level of minoxidil is maintained in a range of about 1 ng/ml to about 20 ng/ml for at least about 8 hours.
3. The method of claim 1, wherein the modified release pharmaceutical formulation further comprises a release modifier.
4. The method of claim 1, wherein the modified release pharmaceutical formulation further comprises a filler, a glidant, a lubricant, or combination thereof.
5. The method of claim 1, wherein the hair loss comprises female pattern hair loss.
6. The method of claim 1, wherein the hair loss comprises alopecia areata.
7. The method of claim 1, wherein the hair loss comprises telogen effluvium.
8. The method of claim 1, wherein the hair loss comprises central centrifugal cicatricial alopecia.
9. The method of claim 1, wherein the hair loss comprises lichen planopilaris.
10. The method of claim 1, wherein the hair loss comprises traction alopecia.
11. The method of claim 1, wherein the oral administration results in hair regrowth.
12. The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a zero order release of minoxidil.

13. The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a pseudo zero order release of minoxidil.
14. The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a first order release of minoxidil.
15. The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a pseudo first order release of minoxidil.
16. The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a second order release of minoxidil.
17. The method of claim 1, wherein the modified release pharmaceutical formulation comprises an enteric coating.
18. The method of claim 1, wherein the modified release pharmaceutical formulation is administered at least once daily.
19. The method of claim 1, wherein the oral administration of the modified release pharmaceutical formulation results in no cardiac effects.
20. The method of claim 15, wherein the cardiac effects are selected from tachycardia, hypotension, premature ventricular contractions, and other tachyarrhythmias.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		
	Filing Date		
	First Named Inventor	Reid WALDMAN	
	Art Unit	N/A	
	Examiner Name	Not yet assigned	
	Attorney Docket Number	135091-00000001	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	11337923	B2	2022-05-24	Yu		
	2	8414919	B2	2013-04-09	Gervais et al.		
	3	9283192	B2	2016-03-15	Mullen et al.		
	4	8268352	B2	2012-09-18	Vaya et al.		
	5	11278499	B2	2022-03-22	Li		
If you wish to add additional U.S. Patent citation information, please click the Add button.							Add
U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	20090004281	A1	2009-01-01	Nghiem et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		
Filing Date		
First Named Inventor	Reid WALDMAN	
Art Unit	N/A	
Examiner Name	Not yet assigned	
Attorney Docket Number	135091-00000001	

	2	20100159001	A1	2010-06-10	Cardinal et al.	
	3	20100104639	A1	2010-04-29	Williams et al.	
	4	20120238608	A1	2012-09-20	Ali et al.	
	5	20190269684	A1	2019-09-05	Sinclair	
	6	20190381296	A1	2019-12-19	Barman et al.	
	7	20090269684	A1	2009-10-29	Fu et al.	
	8	20220047608	A1	2022-02-17	Dharmarajan	
	9	20220296486	A1	2022-09-22	Goren et al.	
	10	20130022677	A1	2013-01-24	Mullen et al.	
	11	20130022676	A1	2013-01-24	Mullen et al.	
	12	20130017262	A1	2013-01-17	Mullen et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		
Filing Date		
First Named Inventor	Reid WALDMAN	
Art Unit	N/A	
Examiner Name	Not yet assigned	
Attorney Docket Number	135091-00000001	

	13	20120301546	A1	2012-11-29	Hassan	
	14	20100310607	A1	2010-12-09	Ju et al.	
	15	20040096499	A1	2004-05-20	Vaya et al.	

If you wish to add additional U.S. Published Application citation information, please click the Add button [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1695708	EP	A2	2006-08-30	Connetics Australia Pty. Ltd.		☐
	2	2004058229	WO	A1	2004-07-15	Biovail Laboratories Inc.		☐
	3	2011100917	AU	A4	2011-09-01	Sinclair, Rodney	with English abstract	☒
	4	110755286	CN	A	2020-02-07	Tong Jing	with English abstract	☒
	5	102003606	KR	A	2019-04-03	Univ Yonsei IACF	with English abstract	☒
	6	0976395	EP	A1	2000-02-02	LIPHA		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number			
	Filing Date			
	First Named Inventor	Reid WALDMAN		
	Art Unit	N/A		
	Examiner Name	Not yet assigned		
	Attorney Docket Number	135091-00000001		

	7	20090029255	KR	A	2009-03-20	Samyang Corp	with English abstract	☒
--	---	-------------	----	---	------------	--------------	-----------------------	-------------------------------------

If you wish to add additional Foreign Patent Document citation information, please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	International Search Report and Written Opinion for Application PCT/US2023/035920 dated February 27, 2024	☐
	2	Junqueira et al. "Coupling of Fused Deposition Modeling and Inkjet Printing to Produce Drug Loaded 3D Printed Tablets" 2022, Pharmaceutics 14(159): 1-13	☐
	3	J.C. Fleishaker et al., "The Pharmacokinetics of 2.5- to 10-mg Oral Doses of Minoxidil in Healthy Volunteers", J. Clin. Pharmacol. (1989) 29: 162-167. (Year: 1989)	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	
Filing Date	
First Named Inventor	Reid WALDMAN
Art Unit	N/A
Examiner Name	Not yet assigned
Attorney Docket Number	135091-00000001

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached timing statement under 37 CFR 1.97(e).
- ☒ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

- ☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

- ☒ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

- ☒ No IDS size fee is required under 37 CFR 1.17(v) at this time.
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/YOUNGHOON KIM/	Date (YYYY-MM-DD)	2025-03-28
Name/Print	"Raph" Younghoon Kim	Registration Number	78,715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	
Filing Date	
First Named Inventor	Reid WALDMAN
Art Unit	N/A
Examiner Name	Not yet assigned
Attorney Docket Number	135091-00000001

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19/094,716
	Filing Date		March 28, 2025
	First Named Inventor	Reid WALDMAN 1629	
	Art Unit	N/A xxxxxxxxxx Raymond J. Henley III	
	Examiner Name	Not yet assigned	
	Attorney Docket Number	135091-00000001	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	11337923	B2	2022-05-24	Yu		
	2	8414919	B2	2013-04-09	Gervais et al.		
	3	9283192	B2	2016-03-15	Mullen et al.		
	4	8268352	B2	2012-09-18	Vaya et al.		
	5	11278499	B2	2022-03-22	Li		
If you wish to add additional U.S. Patent citation information, please click the Add button.							Add
U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	20090004281	A1	2009-01-01	Nghiem et al.		

/RAYMOND J HENLEY III/ (04/23/2025)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		
Filing Date		
First Named Inventor	Reid WALDMAN	
Art Unit	N/A	
Examiner Name	Not yet assigned	
Attorney Docket Number	135091-00000001	

2	20100159001	A1	2010-06-10	Cardinal et al.	
3	20100104639	A1	2010-04-29	Williams et al.	
4	20120238608	A1	2012-09-20	Ali et al.	
5	20190269684	A1	2019-09-05	Sinclair	
6	20190381296	A1	2019-12-19	Barman et al.	
7	20090269684	A1	2009-10-29	Fu et al.	
8	20220047608	A1	2022-02-17	Dharmarajan	
9	20220296486	A1	2022-09-22	Goren et al.	
10	20130022677	A1	2013-01-24	Mullen et al.	
11	20130022676	A1	2013-01-24	Mullen et al.	
12	20130017262	A1	2013-01-17	Mullen et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number			
	Filing Date			
	First Named Inventor	Reid WALDMAN		
	Art Unit	N/A		
	Examiner Name	Not yet assigned		
	Attorney Docket Number	135091-00000001		

	13	20120301546	A1	2012-11-29	Hassan	
	14	20100310607	A1	2010-12-09	Ju et al.	
	15	20040096499	A1	2004-05-20	Vaya et al.	

If you wish to add additional U.S. Published Application citation information, please click the Add button

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1695708	EP	A2	2006-08-30	Connetics Australia Pty. Ltd.		☐
	2	2004058229	WO	A1	2004-07-15	Biovail Laboratories Inc.		☐
	3	2011100917	AU	A4	2011-09-01	Sinclair, Rodney	with English abstract	☒
	4	110755286	CN	A	2020-02-07	Tong Jing	with English abstract	☒
	5	102003606	KR	A	2019-04-03	Univ Yonsei IACF	with English abstract	☒
	6	0976395	EP	A1	2000-02-02	LIPHA		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number			
	Filing Date			
	First Named Inventor	Reid WALDMAN		
	Art Unit	N/A		
	Examiner Name	Not yet assigned		
	Attorney Docket Number	135091-00000001		

	7	20090029255	KR	A	2009-03-20	Samyang Corp	with English abstract	☒
--	---	-------------	----	---	------------	--------------	-----------------------	-------------------------------------

If you wish to add additional Foreign Patent Document citation information, please click the Add button **Add**

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	International Search Report and Written Opinion for Application PCT/US2023/035920 dated February 27, 2024	☐
	2	Junqueira et al. "Coupling of Fused Deposition Modeling and Inkjet Printing to Produce Drug Loaded 30 Printed Tablets" 2022, Pharmaceutics 14(159): 1-13	☐
	3	J.C. Fleishaker et al., "The Pharmacokinetics of 2.5- to 10-mg Oral Doses of Minoxidil in Healthy Volunteers", J. Clin. Pharmacol. (1989) 29: 162-167. (Year: 1989)	☐

If you wish to add additional non-patent literature document citation information, please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/RAYMOND J HENLEY III/ (04/23/2025)	Date Considered	
--------------------	-------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	
Filing Date	
First Named Inventor	Reid WALDMAN
Art Unit	N/A
Examiner Name	Not yet assigned
Attorney Docket Number	135091-00000001

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached timing statement under 37 CFR 1.97(e).

☒ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

☒ No IDS size fee is required under 37 CFR 1.17(v) at this time.

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/YOUNGHOON KIM/	Date (YYYY-MM-DD)	2025-03-28
Name/Print	"Raph" Younghoon Kim	Registration Number	78,715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	
Filing Date	
First Named Inventor	Reid WALDMAN
Art Unit	N/A
Examiner Name	Not yet assigned
Attorney Docket Number	135091-00000001

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716
	Filing Date		2025-03-28
	First Named Inventor	Reid Waldman	
	Art Unit	1629	
	Examiner Name	Raymond J Henley III	
	Attorney Docket Number	135091-0001CT04	

U.S. PATENTS Remove						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	7776844	B2	2010-08-17	Yu et al.	
	2	8835376	B2	2014-09-16	Shen et al.	
	3	9011907	B2	2015-04-21	Ravishankar et al.	
	4	7871643	B2	2011-01-18	Lizio et al.	
	5	7915247	B1	2011-03-29	Arnold et al.	
	6	8268352	B2	2012-09-18	Vaya et al.	
	7	8349297	B2	2013-01-08	Brown et al.	
	8	8414919	B2	2013-04-09	Gervais et al.	

/RAYMOND J HENLEY III/ (06/10/2025)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid Waldman		
	Art Unit		1629	
	Examiner Name	Raymond J Henley III		
	Attorney Docket Number		135091-0001CT04	

	9	9023386	B2	2015-05-05	Benita et al.	
	10	9060936	B2	2015-05-05	Berndl et al.	
	11	9161917	B2	2015-10-20	Faure et al.	
	12	9205047	B2	2015-12-08	Shoichet et al.	
	13	9237760	B2	2016-01-19	Ravishankar et al.	
	14	9283192	B2	2016-03-15	Mullen et al.	
	15	9730866	B2	2017-08-15	Hashimoto et al.	
	16	9750701	B2	2017-09-05	Jans et al.	
	17	10076500	B2	2018-09-18	Grenier et al.	
	18	10143626	B2	2018-12-04	Li	
	19	10272086	B2	2019-04-30	Hsu	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid Waldman		
	Art Unit		1629	
	Examiner Name	Raymond J Henley III		
	Attorney Docket Number		135091-0001CT04	

	20	10314787	B2	2019-06-11	Odidi et al.	
	21	10500282	B2	2019-12-10	Desai et al.	
	22	10512670	B2	2019-12-24	Song et al.	
	23	10561593	B2	2020-02-18	Wu	
	24	10653718	B2	2020-05-19	Joanny Menvielle-bourg	
	25	10933024	B2	2021-03-02	Baer et al.	
	26	11116770	B2	2021-09-14	Sinclair	
	27	11147766	B2	2021-10-19	Zalit et al.	
	28	11278499	B2	2022-03-22	Li	
	29	11318107	B2	2022-05-03	Vasisht et al.	
	30	11337923	B2	2022-05-24	Yu	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid Waldman		
	Art Unit		1629	
	Examiner Name	Raymond J Henley III		
	Attorney Docket Number		135091-0001CT04	

	31	11819576	B2	2023-11-21	Damm et al.	
	32	12263323	B2	2025-04-01	Barman et al.	
	33	12268688	B2	2025-04-08	Waldman	

If you wish to add additional U.S. Patent citation information, please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040096499	A1	2004-05-20	Vaya et al.	
	2	20090004281	A1	2009-01-01	Nghiem et al.	
	3	20090269684	A1	2009-10-29	Fu et al.	
	4	20100104639	A1	2010-04-29	Williams et al.	
	5	20100159001	A1	2010-06-10	Cardinal et al.	
	6	20100310607	A1	2010-12-09	Ju et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid Waldman	
Art Unit		1629
Examiner Name	Raymond J Henley III	
Attorney Docket Number		135091-0001CT04

7	20120238608	A1	2012-09-20	Ali et al.	
8	20120301546	A1	2012-11-29	Hassan	
9	20130017262	A1	2013-01-17	Mullen et al.	
10	20130022676	A1	2013-01-24	Mullen et al.	
11	20130022677	A1	2013-01-24	Mullen et al.	
12	20190269684	A1	2019-09-05	Sinclair	
13	20190381296	A1	2019-12-19	Barman et al.	
14	20210161820	A1	2021-06-03	Sei et al.	
15	20220047608	A1	2022-02-17	Dharmarajan	
16	20220296486	A1	2022-09-22	Goren et al.	
17	20230181468	A1	2023-06-15	Di Miguel et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid Waldman		
	Art Unit		1629	
	Examiner Name	Raymond J Henley III		
	Attorney Docket Number		135091-0001CT04	

	18	20230355643	A1	2023-11-09	Minakar et al.	
	19	20240000746	A1	2024-01-04	Minakar et al.	
	20	20240009192	A1	2024-01-11	Zhang	
	21	20240325350	A1	2024-10-03	Dandiker	
	22	20250064807	A1	2025-02-27	Sinclair	
	23	20250073161	A1	2025-03-06	Sheu et al.	

If you wish to add additional U.S. Published Application citation information, please click the Add button

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2011100917	AU	A4	2011-09-01	Sinclair, Rodney		☐
	2	110755286	CN	A	2020-02-07	Tong Jing		☐
	3	1695708	EP	A2	2006-08-30	Connetics Australia Pty. Ltd.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid Waldman		
	Art Unit		1629	
	Examiner Name	Raymond J Henley III		
	Attorney Docket Number		135091-0001CT04	

	4	976395	EP	A1	2000-02-02	Bonhomme et al.		☐
	5	102003606	KR	A	2019-04-03	Sung et al.		☐
	6	20090029255	KR	A	2009-03-20	Samyang Corp		☐
	7	2004058229	WO	A1	2004-07-15	Biovail Laboratories Inc.		☐
	8	2024254056	WO	A1	2024-12-12	Fang		☐
	9	2024189607	WO	A1	2024-09-19	Didenko		☐
	10	2024125086	WO	A1	2024-06-20	Jiang et al.		☐
	11	2024199216	WO	A1	2024-10-03	Qi et al.		☐
	12	2024124206	WO	A1	2024-06-13	Paus		☐
	13	2024091572	WO	A1	2024-05-02	Waldman		☐

If you wish to add additional Foreign Patent Document citation information, please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716
	Filing Date		2025-03-28
	First Named Inventor	Reid Waldman	
	Art Unit	1629	
	Examiner Name	Raymond J Henley III	
	Attorney Docket Number	135091-0001CT04	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/R.J.H/	1	International Search Report and Written Opinion for Application PCT/US2023/035920 dated February 27, 2024	☐
/R.J.H/	2	Junqueira et al. "Coupling of Fused Deposition Modeling and Inkjet Printing to Produce Drug Loaded 3D Printed Tablets" 2022, Pharmaceutics 14(159): 1-13	☐
/R.J.H/	3	"Reynolds et al "Investigation of the Effect of Tablet Surface Area/Volume on Drug Release from Hydroxypropylmethylcellulose Controlled-Release Matrix Tablets"" Drug Development and Industrial Pharmacy, 28(4), 457-466 (2002)"	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/RAYMOND J HENLEY III/ (06/10/2025)	Date Considered	
--------------------	-------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	Raymond J Henley III
Attorney Docket Number	135091-0001CT04

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached timing statement under 37 CFR 1.97(e).
- ☒ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

- ☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

- ☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

- ☐ No IDS size fee is required under 37 CFR 1.17(v) at this time.
- ☒ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/Erica A. Spence/	Date (YYYY-MM-DD)	2025-05-27
Name/Print	Erica A. Spence, Pharm D	Registration Number	81472

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	Raymond J Henley III
Attorney Docket Number	135091-0001CT04

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716
	Filing Date		2025-03-28
	First Named Inventor	Reid WALDMAN	
	Art Unit	1629	
	Examiner Name	RAYMOND J HENLEY III	
	Attorney Docket Number	135091-0001CT04	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	6383471	B1	2002-05-07	Chen et al.		
	2	6485950	B1	2002-11-26	Kumar et al.		
	3	6849661	B2	2005-02-01	Kelly et al.		
	4	7037697	B2	2006-05-02	Kumar et al.		
	5	7749533	B2	2010-07-06	Fu et al.		
	6	8858993	B2	2014-10-14	Gold et al.		
	7	9254268	B2	2016-02-09	Temtsin Krayz et al.		
	8	9371330	B2	2016-06-21	Kahn et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit		1629
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number		135091-0001CT04

	9	9839644	B2	2017-12-12	Kumar	
	10	10092568	B2	2018-10-09	Kahn et al.	
	11	11504342	B2	2022-12-22	Vasisht et al.	
	12	8173161	B2	2012-05-08	Bunick et al.	
	13	8231902	B2	2012-07-31	Solomon et al.	
	14	8263125	B2	2012-09-11	Vaya et al.	
	15	8383155	B2	2013-02-26	Bar-shalom et al.	
	16	8394409	B2	2013-03-12	Odidi et al.	
	17	8529939	B2	2013-09-10	Masters et al.	
	18	8591945	B2	2013-11-26	Vandecruys et al	
	19	8613285	B2	2013-12-24	Fuisz	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit		1629
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number		135091-0001CT04

	20	8920834	B2	2014-12-30	Rahmouni et al.	
	21	8927014	B2	2015-01-06	Rahmouni et al.	
	22	8962064	B2	2015-02-24	Kolter et al.	
	23	11547839	B2	2023-01-10	Menachem et al.	
	24	9029427	B2	2016-05-31	Endo et al.	
	25	9351940	B2	2016-05-31	Salman et al.	
	26	9402909	B2	2016-08-02	Liepold et al.	
	27	9468644	B2	2016-10-18	Kalem	
	28	9474719	B2	2016-10-25	Mullen et al.	
	29	9554989	B2	2017-01-31	Kaplan et al.	
	30	9555006	B2	2017-01-31	Petereit et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid WALDMAN		
	Art Unit		1629	
	Examiner Name	RAYMOND J HENLEY III		
	Attorney Docket Number		135091-0001CT04	

	31	9687451	B2	2017-06-27	Rubino et al.	
	32	9730899	B2	2017-08-15	Bar et al.	
	33	9974753	B2	2018-05-22	Salman et al.	
	34	9993439	B2	2018-06-12	Gu et al.	
	35	10624858	B2	2020-04-21	Odidi et al.	
	36	11065205	B2	2021-07-20	Mullen et al.	
	37	11285102	B2	2022-03-29	Menachem et al.	
	38	11318088	B2	2022-05-03	Popov	

If you wish to add additional U.S. Patent citation information, please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020035070	A1	2002-03-21	Gardlik et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit		1629
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number		135091-0001CT04

	2	20020119174	A1	2002-08-29	Gardlik et al.	
	3	20030064494	A1	2003-04-03	Kumar	
	4	20030091630	A1	2003-05-15	Louie-helm et al.	
	5	20030092765	A1	2003-05-15	Kelly et al.	
	6	20030124191	A1	2003-07-03	Besse et al.	
	7	20030133985	A1	2003-07-17	Louie-helm et al.	
	8	20030152622	A1	2003-08-14	Louie-helm et al.	
	9	20040063784	A1	2004-04-01	Kelly et al.	
	10	20050013857	A1	2005-01-20	Fu et al.	
	11	20050118272	A1	2005-06-02	Besse et al.	
	12	20050276836	A1	2005-12-15	Wilson et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit		1629
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number		135091-0001CT04

	13	20060280791	A1	2006-12-14	Ju et al.	
	14	20070020331	A1	2007-01-25	Gold et al.	
	15	20070148234	A1	2007-06-28	Ju et al.	
	16	20080292560	A1	2008-11-27	Tamarkin et al.	
	17	20090098200	A1	2009-04-16	Temtsin et al.	
	18	20100028439	A1	2010-02-04	Jenkins et al.	
	19	20100047322	A1	2010-02-25	Hoffman et al.	
	20	20100316678	A1	2010-12-16	Goodchild et al.	
	21	20120171262	A1	2012-07-05	Ju et al.	
	22	20130078284	A1	2013-03-28	Ju et al.	
	23	20130203766	A1	2013-08-08	Mendla et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit		1629
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number		135091-0001CT04

	24	20130280233	A1	2013-10-24	Kahn et al.	
	25	20150231069	A1	2015-08-20	Modi	
	26	20150232468	A1	2015-08-20	Kahn et al.	
	27	20160067217	A1	2016-03-10	Kumar	
	28	20160213694	A1	2016-07-28	Kumar	
	29	20160220505	A1	2016-08-04	Temtsin Krayz et al.	
	30	20180042945	A1	2028-02-15	Kumar	
	31	20210030693	A1	2021-02-04	Vasisht et al.	
	32	20210085622	A1	2021-03-25	Vasisht et al.	
	33	20100172993	A1	2010-07-08	Singh et al.	
	34	20190269684	A1	2019-09-05	Sinclair	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid WALDMAN		
	Art Unit		1629	
	Examiner Name	RAYMOND J HENLEY III		
	Attorney Docket Number		135091-0001CT04	

	35	20200214958	A1	2020-07-09	Goren et al.	
	36	20210186880	A1	2021-06-24	Mathiowitz et al.	
	37	20210299044	A1	2021-09-30	Fossel	
	38	20210338671	A1	2021-11-04	Williams et al.	
	39	20220054425	A1	2022-02-24	Choi et al.	
	40	20220160872	A1	2022-05-26	Yadavalli et al.	

If you wish to add additional U.S. Published Application citation information, please click the Add button

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	202421055307	IN	A	2024-10-04	Bhowate et al.		☒
	2	7222236	JP	B2	2023-02-15	Wakui		☒
	3	2019172655	JP	A	2019-10-10	Wakui		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit	1629	
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number	135091-0001CT04	

4	20080026754	KR	A1	2008-03-26	Park et al.		☒
5	2000059475	WO	A1	2000-10-12	Chen et al.		☐
6	2002007685	WO	A2	2002-01-31	Gardlik et al.		☐
7	2002007700	WO	A2	2002-01-31	Gardlik et al.		☐
8	2003055464	WO	A1	2003-07-10	Besse et al.		☐
9	2004032919	WO	A1	2004-04-22	Kelly et al.		☐
10	2004100857	WO	A2	2004-11-25	Fu et al.		☐
11	2005017134	WO	A1	2005-02-24	Dixit et al.		☐
12	2006057637	WO	A1	2006-06-01	Yoo		☐
13	2007014061	WO	A2	2007-02-01	Gold et al.		☐
14	2007144082	WO	A2	2007-12-21	Hoffman et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit	1629	
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number	135091-0001CT04	

15	2009000038	WO	A1	2008-12-31	Goodchild		☐
16	2009040818	WO	A1	2009-04-02	Temtsin Krayz et al.		☐
17	2009040818	WO	A9	2010-05-20	Temtsin Krayz et al.		☐
18	2012068299	WO	A2	2012-05-24	Kahn et al.		☐
19	2012068299	WO	A9	2012-06-20	Kahn et al.		☐
20	2016040462	WO	A2	2012-06-20	Kumar		☐
21	2019165208	WO	A1	2019-08-29	Vasisht et al.		☐
22	2021107926	WO	A1	2021-06-03	Leach		☐
23	2012059936	WO	A1	2012-05-10	Devarajan et al.		☐
24	2012059936	WO	A4	2012-05-10	Devarajan et al.	Corresponds to IN3053/ MUM/2010	☐
25	2011100917	AU	B4	2013-05-02	Sinclair, Rodney		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit	1629	
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number	135091-0001CT04	

26	2576556	CA	C	2014-04-08	Odidi et al.		☐
27	2579382	CA	C	2015-05-26	Odidi et al.		☐
28	2705083	CA	C	2017-09-12	Schoichet et al.		☐
29	113413405	CN	A	2021-09-21	Li		☒
30	114129527	CN	A	2022-03-04	Ning et al.		☒
31	2863896	EP	B1	2016-09-14	Francas et al.		☐
32	3689324	EP	A1	2020-08-05	Join et al.		☐
33	202211025909	IN	A	2022-05-13	Manoj et al.		☐
34	208784	IN	B	2007-05-05	Mehendre et al.		☐
35	3053/MUM/2010	IN	A	2013-06-21	Devarajan et al.	Corresponds to WO2012059936A4	☐
36	2021031438	JP	A	2021-03-01	Usui		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716	
	Filing Date		2025-03-28	
	First Named Inventor	Reid WALDMAN		
	Art Unit	1629		
	Examiner Name	RAYMOND J HENLEY III		
	Attorney Docket Number	135091-0001CT04		

	37	7118743	JP	B2	2022-08-16	Usui		☒
	38	2010005067	MX	A	2011-11-23	Ramirez		☐
	39	102003606	KR	B1	2019-07-18	Sung et al.		☒

If you wish to add additional Foreign Patent Document citation information, please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	VAHABI-AMLASHI ET. AL. "A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss" Dermatologic Therapy, September 2021, https://doi.org/10.1111/dth.15131	☐
	2	PANCHAPRATEEP et al., "Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment" Dermatol Ther (Heidelb) (2020) 10:1345-1357	☐
	3	RODRIGUES-BARATA ET. AL. "Low-Dose Oral Minoxidil for Female Pattern Hair Loss: A Unicenter Descriptive Study of 148 Women" Skin Appendage Disord. 2020 Feb 21;6(3):175–176. doi: 10.1159/000505820	☐
	4	VAÑÓ-GALVÁN ET. AL. "Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients" Journal of the American Academy of Dermatology, Volume 84, Issue 6, June 2021, Pages 1644-1651	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid WALDMAN
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid WALDMAN
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached timing statement under 37 CFR 1.97(e).
- ☐ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

- ☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

- ☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

- ☐ No IDS size fee is required under 37 CFR 1.17(v) at this time.
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).
- ☒ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).
- ☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/YOUNGHOON KIM/	Date (YYYY-MM-DD)	2025-06-27
Name/Print	"Raph" Younghoon Kim	Registration Number	78,715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid WALDMAN
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

<i>Search Notes</i> 	Application/Control No. 19/094,716	Applicant(s)/Patent Under Reexamination WALDMAN, Reid
	Examiner RAYMOND J HENLEY III	Art Unit 1629

CPC - Searched*		
Symbol	Date	Examiner
A61K 31/506	04/23/2025	RJH

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner
514	275	04/23/2025	RJH

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
PALM/PE2E Applicant/Inventor search	04/23/2025	RJH
STN art search, (summary in file)	04/23/2025	RJH

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner

/RAYMOND J HENLEY III/ Primary Examiner, Art Unit 1629	
---	--



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	03/28/2025	Reid WALDMAN	135091-00000001	3586
27189 7590 04/28/2025 PROCOPIO, CORY, HARGREAVES & SAVITCH LLP 525 B STREET SUITE 2200 SAN DIEGO, CA 92101			EXAMINER HENLEY III, RAYMOND J	
			ART UNIT	PAPER NUMBER
			1629	
			NOTIFICATION DATE	DELIVERY MODE
			04/28/2025	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTONotifications@procopio.com
docketing@procopio.com

CLAIMS 1-20 ARE PRESENTED FOR EXAMINATION

Notice of Pre-AIA or AIA Status

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Applicant's Information Disclosure Statement filed March 28, 2025 has been received and entered into the application. As reflected by the attached, completed copies of form PTO/SB/08, the cited references have been considered by the Examiner.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the

examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 *et seq.* for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.

Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 12,268,688, (cited by the Examiner).

Although the claims at issue are not identical, they are not patentably distinct from each other because the currently claimed minoxidil dosage amount and resulting blood concentration

range fall within or overlap with the dosage amount and blood concentration range set forth in at least claim 1 of the patented claim set thus making obvious the currently claimed subject matter.

Accordingly, the claims are deemed properly rejected and none are currently in condition for allowance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYMOND J HENLEY III whose telephone number is (571)272-0575. The examiner can normally be reached M-F 6-2:30pm EST.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey S Lundgren can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: <https://patentcenter.uspto.gov>. Visit <https://www.uspto.gov/patents/apply/patent-center> for more information about Patent Center and <https://www.uspto.gov/patents/docx> for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/RAYMOND J HENLEY III/
Primary Examiner, Art Unit 1629
April 23, 2025

<i>Notice of References Cited</i>	Application/Control No. 19/094,716		Applicant(s)/Patent Under Reexamination WALDMAN, Reid	
	Examiner RAYMOND J HENLEY III		Art Unit 1629	Page 1 of 1

U.S. PATENT DOCUMENTS						
*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Name	CPC Classification	US Classification
*	A	US-12268688-B2	2025-04-08	Waldman; Reid	A61K9/2054	1/1
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS					
*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Country	CPC Classification
	N				
	O				
	P				
	Q				
	R				
	S				
	T				

NON-PATENT DOCUMENTS		
*		Include as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
 Dates in YYYY-MM-DD format are publication dates. Classifications may be US or foreign.



Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

APPROVAL LETTER

APPLICATION #
19/094,716

FILING DATE
03/28/2025

APPLICANT/PATENT UNDER REEXAMINATION
Reid WALDMAN

Title of Invention

COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Electronic terminal disclaimer filed on 05/28/2025



Approved

This patent is subject to a Terminal Disclaimer

Approved / Disapproved by: Electronic Terminal Disclaimer automatically approved

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Reid Waldman

Application No.: 19/094,716

Filing Date: March 28, 2025

Confirm. No.: 3586

Examiner: Raymond Henley
III

Group Art Unit: 1629

Attorney Docket No.: 135091-0001CT04

For: COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE
MINOXIDIL

REPLY TO OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In response to the Non-Final Office Action, dated April 28, 2025, Applicant respectfully submits the following:

Amendments to the Claims begin on page 2 of this paper; and

Remarks begin on page 5 of this paper.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Reid Waldman

Application No.: 19/094,716

Filing Date: March 28, 2025

Confirm. No.: 3586

Examiner: Raymond Henley
III

Group Art Unit: 1629

Attorney Docket No.: 135091-0001CT04

For: COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE
MINOXIDIL

REPLY TO OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In response to the Non-Final Office Action, dated April 28, 2025, Applicant respectfully submits the following:

Amendments to the Claims begin on page 2 of this paper; and

Remarks begin on page 5 of this paper.

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of and listings of claims.

1. (Original) A method of treating hair loss, comprising orally administering to a human subject who is experiencing hair loss a modified release pharmaceutical formulation comprising about 4.5 mg of minoxidil or a molar equivalent amount of the pharmaceutically acceptable salt thereof; wherein the modified release pharmaceutical formulation provides:

a $C_{\max}$ of minoxidil that is about 0.25 ng/ml to about 20 ng/ml; and

a $T_{\max}$ of minoxidil that is about 30 to about 360 minutes.

2. (Original) The method of claim 1, wherein a blood level of minoxidil is maintained in a range of about 1 ng/ml to about 20 ng/ml for at least about 8 hours.

3. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation further comprises a release modifier.

4. (Currently Amended) The method of claim 1, wherein the modified release pharmaceutical formulation further comprises a filler, a glidant, a lubricant, or a combination thereof.

5. (Original) The method of claim 1, wherein the hair loss comprises female pattern hair loss.

6. (Original) The method of claim 1, wherein the hair loss comprises alopecia areata.

7. (Original) The method of claim 1, wherein the hair loss comprises telogen effluvium.

8. (Original) The method of claim 1, wherein the hair loss comprises central centrifugal cicatricial alopecia.

9. (Original) The method of claim 1, wherein the hair loss comprises lichen planopilaris.

10. (Original) The method of claim 1, wherein the hair loss comprises traction alopecia.

11. (Original) The method of claim 1, wherein the oral administration results in hair regrowth.

12. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a zero order release of minoxidil.

13. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a pseudo zero order release of minoxidil.

14. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a first order release of minoxidil.

15. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a pseudo first order release of minoxidil.

16. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation exhibits a second order release of minoxidil.

17. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation comprises an enteric coating.

18. (Original) The method of claim 1, wherein the modified release pharmaceutical formulation is administered at least once daily.

19. (Original) The method of claim 1, wherein the oral administration of the modified release pharmaceutical formulation results in no cardiac effects.

20. (Currently Amended) The method of ~~claim 15~~claim 19, wherein the cardiac effects are selected from tachycardia, hypotension, premature ventricular contractions, and other tachyarrhythmias.

REMARKS

Claims 1–20 were previously pending in the present application. By the present amendment, claims 4 and 20 have been amended. No claim has been canceled. No claim has been added. Accordingly, Claims 1–20 are presented for further consideration, with claim 1 being independent. No new matter is added.

In light of the claim amendments and remarks submitted herewith, reconsideration and withdrawal of the rejections raised in the Office Action are respectfully requested.

1. **Response to Rejections of Claims 1-20 for Double Patenting**

The Office Action rejects Claims 1-20 on the ground of non-statutory obviousness-type double patenting as allegedly being unpatentable over Claims 1-28 of U.S. Patent No. 12,268,688.

While Applicant does not admit that the rejection is correct, Applicant has submitted herewith a timely filed terminal disclaimer in compliance with 37 C.F.R. 1.321(c). Accordingly, Applicant respectfully requests that this rejection of Claims 1-20 be withdrawn.

2. **No Disclaimers or Disavowals**

Applicant respectfully submits that the claims are in condition for allowance. Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Furthermore, any remarks referring to only a portion of a claim should not be understood to base patentability on that portion or to imply that the limitation discussed is essential or critical. Rather, patentability must rest on each claim taken as a whole and not on any particular feature or combination of features. References to the specification should not be read into the claims for claim construction purposes, but merely represent non-limiting embodiments of the claimed subject matter.

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, no acquiescence, disclaimer, or estoppel is intended or should be inferred thereby. Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made only to clarify the claimed elements, address informalities, and/or expedite prosecution of the present application, and are without prejudice to the presentation or assertion, in the future, of claims relating to the same or similar subject matter. Applicant may not have presented, in all cases, arguments concerning whether the applied references render the

claims anticipated or obvious, and Applicant reserves the right to later submit additional or alternative arguments of patentability. Applicant also reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application, and any prior or alleged disclaimers or disavowals are hereby rescinded.

3. **Conclusion**

Based on the above amendments and remarks, Applicant believes that the claims are in condition for allowance and such is respectfully requested. Applicant believes that no additional claim fees are necessitated by this response.

If there is any outstanding issue, which the Examiner feels may be best resolved by a telephone interview, the Examiner is kindly requested to contact the undersigned to discuss any such issues.

Please charge any additional fees, including any fees for extensions of time, or credit any overpayment to Deposit Account No. **502075**.

Respectfully submitted,

Procopio, Cory, Hargreaves & Savitch LLP

Dated: May 30, 2025

By: /YOUNGHOON KIM/
"Raph" Younghoon Kim, Reg. No. 78,715

PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B Street, Suite 2200
San Diego, California 92101
(619) 238-1900 (Phone)
(619) 235-0398 (Fax)
Customer No. 27189

REMARKS

Claims 1–20 were previously pending in the present application. By the present amendment, claims 4 and 20 have been amended. No claim has been canceled. No claim has been added. Accordingly, Claims 1–20 are presented for further consideration, with claim 1 being independent. No new matter is added.

In light of the claim amendments and remarks submitted herewith, reconsideration and withdrawal of the rejections raised in the Office Action are respectfully requested.

1. **Response to Rejections of Claims 1-20 for Double Patenting**

The Office Action rejects Claims 1-20 on the ground of non-statutory obviousness-type double patenting as allegedly being unpatentable over Claims 1-28 of U.S. Patent No. 12,268,688.

While Applicant does not admit that the rejection is correct, Applicant has submitted herewith a timely filed terminal disclaimer in compliance with 37 C.F.R. 1.321(c). Accordingly, Applicant respectfully requests that this rejection of Claims 1-20 be withdrawn.

2. **No Disclaimers or Disavowals**

Applicant respectfully submits that the claims are in condition for allowance. Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Furthermore, any remarks referring to only a portion of a claim should not be understood to base patentability on that portion or to imply that the limitation discussed is essential or critical. Rather, patentability must rest on each claim taken as a whole and not on any particular feature or combination of features. References to the specification should not be read into the claims for claim construction purposes, but merely represent non-limiting embodiments of the claimed subject matter.

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, no acquiescence, disclaimer, or estoppel is intended or should be inferred thereby. Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made only to clarify the claimed elements, address informalities, and/or expedite prosecution of the present application, and are without prejudice to the presentation or assertion, in the future, of claims relating to the same or similar subject matter. Applicant may not have presented, in all cases, arguments concerning whether the applied references render the

claims anticipated or obvious, and Applicant reserves the right to later submit additional or alternative arguments of patentability. Applicant also reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application, and any prior or alleged disclaimers or disavowals are hereby rescinded.

3. **Conclusion**

Based on the above amendments and remarks, Applicant believes that the claims are in condition for allowance and such is respectfully requested. Applicant believes that no additional claim fees are necessitated by this response.

If there is any outstanding issue, which the Examiner feels may be best resolved by a telephone interview, the Examiner is kindly requested to contact the undersigned to discuss any such issues.

Please charge any additional fees, including any fees for extensions of time, or credit any overpayment to Deposit Account No. **502075**.

Respectfully submitted,
Procopio, Cory, Hargreaves & Savitch LLP

Dated: May 30, 2025

By: /YOUNGHOON KIM/
"Raph" Younghoon Kim, Reg. No. 78,715

PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B Street, Suite 2200
San Diego, California 92101
(619) 238-1900 (Phone)
(619) 235-0398 (Fax)
Customer No. 27189

<i>Search Notes</i> 	Application/Control No. 19/094,716	Applicant(s)/Patent Under Reexamination WALDMAN, Reid
	Examiner RAYMOND J HENLEY III	Art Unit 1629

CPC - Searched*		
Symbol	Date	Examiner
A61K 31/506	04/23/2025	RJH
updated	06/10/2025	RJH

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner
514	275	04/23/2025	RJH
	updated	06/10/2025	RJH

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
PALM/PE2E Applicant/Inventor search	04/23/2025	RJH
STN art search, (summary in file)	04/23/2025	RJH
updated	06/10/2025	RJH

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
	See the STN search noted above	06/10/2025	RJH

/RAYMOND J HENLEY III/ Primary Examiner, Art Unit 1629	
---	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	19094716
	Filing Date	2025-03-28
	First Named Inventor	Reid Waldman
	Art Unit	1629
	Examiner Name	RAYMOND J HENLEY III
	Attorney Docket Number	135091-0001CT04

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information, please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	20240374594	A1	2024-11-14	Sinha		
	2	20070212416	A1	2007-09-13	Rubino et al.		

If you wish to add additional U.S. Published Application citation information, please click the Add button

Add

FOREIGN PATENT DOCUMENTS									Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵	
	1							☐	

If you wish to add additional Foreign Patent Document citation information, please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS									Remove
---------------------------------	--	--	--	--	--	--	--	--	--------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716
	Filing Date		2025-03-28
	First Named Inventor	Reid Waldman	
	Art Unit	1629	
	Examiner Name	RAYMOND J HENLEY III	
	Attorney Docket Number	135091-0001CT04	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	VILLANI et al., Review of oral minoxidil as treatment of hair disorders: In search of the perfect dose, J. European Academy of Dermatology and Venereology, 2021 (Abstract Only)	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☒ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached timing statement under 37 CFR 1.97(e).

☐ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

☒ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

☒ No IDS size fee is required under 37 CFR 1.17(v) at this time.

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/YOUNGHOON KIM/	Date (YYYY-MM-DD)	2025-09-05
Name/Print	"Raph" Younghoon Kim	Registration Number	78715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	19094716
	Filing Date	2025-03-28
	First Named Inventor	Reid Waldman
	Art Unit	1629
	Examiner Name	RAYMOND J HENLEY III
	Attorney Docket Number	135091-0001CT04

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information, please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
/R.J.H/	1	20240374594	A1	2024-11-14	Sinha		
/R.J.H/	2	20070212416	A1	2007-09-13	Rubino et al.		

If you wish to add additional U.S. Published Application citation information, please click the Add button

Add

FOREIGN PATENT DOCUMENTS									Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵	
	1							☐	

If you wish to add additional Foreign Patent Document citation information, please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS									Remove
---------------------------------	--	--	--	--	--	--	--	--	--------

/RAYMOND J HENLEY III/ (10/20/2025)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716
	Filing Date		2025-03-28
	First Named Inventor	Reid Waldman	
	Art Unit	1629	
	Examiner Name	RAYMOND J HENLEY III	
	Attorney Docket Number	135091-0001CT04	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/R.J.H./	1	VILLANI et al., Review of oral minoxidil as treatment of hair disorders: In search of the perfect dose, J. European Academy of Dermatology and Venereology, 2021 (Abstract Only)	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/RAYMOND J HENLEY III/ (10/20/2025)	Date Considered	
--------------------	-------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		19094716
	Filing Date		2025-03-28
	First Named Inventor	Reid Waldman	
	Art Unit	1629	
	Examiner Name	RAYMOND J HENLEY III	
	Attorney Docket Number	135091-0001CT04	

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☒ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached timing statement under 37 CFR 1.97(e).

☐ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

☒ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

☒ No IDS size fee is required under 37 CFR 1.17(v) at this time.

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/YOUNGHOON KIM/	Date (YYYY-MM-DD)	2025-09-05
Name/Print	"Raph" Younghoon Kim	Registration Number	78715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	19094716
	Filing Date	2025-03-28
	First Named Inventor	Reid Waldman
	Art Unit	1629
	Examiner Name	RAYMOND J HENLEY III
	Attorney Docket Number	135091-0001CT04

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information, please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information, please click the Add button

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/R. J. H./	1	118304268	CN	A	2024-07-09	Shanghai Aoquan Biomedical Tech Co Ltd		☒

If you wish to add additional Foreign Patent Document citation information, please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

/RAYMOND J HENLEY III/ (10/20/2025)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

/R.J.H/	1	FAN et al., "An Artificial Neural Network for Multi-objective Simultaneous Optimization of HPMC Sustained Release Tablet Formulations", Journal of Chinese Pharmaceutical Sciences, Vol. 39, No. 10, October 2004, pp. 768-771.	☐
/R.J.H/	2	LONITEN Minoxidil 10 mg Tablet Bottle, Pfizer Australia Pty Ltd, Australian Register of Therapeutic Goods (ARTG) Entry: 12309, Available online at URL< https://www.tga.gov.au/resources/artg/12309 >, August 2, 1991, 2 pages.	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/RAYMOND J HENLEY III/ (10/20/2025)	Date Considered	
--------------------	-------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	19094716
	Filing Date	2025-03-28
	First Named Inventor	Reid Waldman
	Art Unit	1629
	Examiner Name	RAYMOND J HENLEY III
	Attorney Docket Number	135091-0001CT04

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☒ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached timing statement under 37 CFR 1.97(e).

☐ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

☒ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37 CFR 1.17(v) and the [IDS Auto-Load Instructions](#) for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

☐ No IDS size fee is required under 37 CFR 1.17(v) at this time.

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).

☒ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/YOUNGHOON KIM/	Date (YYYY-MM-DD)	2025-09-18
Name/Print	"Raph" Younghoon Kim	Registration Number	78715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	19094716
Filing Date	2025-03-28
First Named Inventor	Reid Waldman
Art Unit	1629
Examiner Name	RAYMOND J HENLEY III
Attorney Docket Number	135091-0001CT04

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		19094716
Filing Date		2025-03-28
First Named Inventor	Reid WALDMAN	
Art Unit	1629	
Examiner Name	RAYMOND J HENLEY III	
Attorney Docket Number	135091-0001CT04	

	9	9839644	B2	2017-12-12	Kumar	
	10	10092568	B2	2018-10-09	Kahn et al.	
Change(s) applied to document /JEB/ 11/17/2025	11	11504342	B2	11/2022 ~~2022-12-22~~	Vasisht et al.	
	12	8173161	B2	2012-05-08	Bunick et al.	
	13	8231902	B2	2012-07-31	Solomon et al.	
	14	8263125	B2	2012-09-11	Vaya et al.	
	15	8383155	B2	2013-02-26	Bar-shalom et al.	
	16	8394409	B2	2013-03-12	Odidi et al.	
	17	8529939	B2	2013-09-10	Masters et al.	
	18	8591945	B2	2013-11-26	Vandecruys et al	
	19	8613285	B2	2013-12-24	Fuisz	



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	03/28/2025	Reid WALDMAN	135091-0001CT04	3586
27189	7590	10/21/2025	EXAMINER	
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP			HENLEY III, RAYMOND J	
525 B STREET				
SUITE 2200				
SAN DIEGO, CA 92101				
			ART UNIT	PAPER NUMBER
			1629	
			NOTIFICATION DATE	DELIVERY MODE
			10/21/2025	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTONotifications@procopio.com
docketing@procopio.com

CORRECTED Notice of Allowability	Application No. 19/094,716	Applicant(s) WALDMAN, Reid	
	Examiner RAYMOND J HENLEY III	Art Unit 1629	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the IDS papers filed September 15 & 18, 2025.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-20. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov**.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1. ☐ Notice of References Cited (PTO-892) | 5. ☐ Examiner's Amendment/Comment |
| 2. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date <u>09/15/2025 & 09/18/2025.</u> | 6. ☐ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material ____. | 7. ☐ Other ____. |
| 4. ☐ Interview Summary (PTO-413),
Paper No./Mail Date. ____. | |

/RAYMOND J HENLEY III/
Primary Examiner, Art Unit 1629



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	03/28/2025	Reid WALDMAN	135091-0001CT04	3586
27189	7590	08/08/2025	EXAMINER	
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP			HENLEY III, RAYMOND J	
525 B STREET				
SUITE 2200				
SAN DIEGO, CA 92101				
			ART UNIT	PAPER NUMBER
			1629	
			NOTIFICATION DATE	DELIVERY MODE
			08/08/2025	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTONotifications@procopio.com
docketing@procopio.com

CORRECTED Notice of Allowability	Application No. 19/094,716	Applicant(s) WALDMAN, Reid	
	Examiner RAYMOND J HENLEY III	Art Unit 1629	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the IDS filed June 27, 2025.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-20 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1. ☐ Notice of References Cited (PTO-892) | 5. ☐ Examiner's Amendment/Comment |
| 2. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date 06/27/2025. | 6. ☐ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material _____. | 7. ☐ Other _____. |
| 4. ☐ Interview Summary (PTO-413),
Paper No./Mail Date. _____. | |

/RAYMOND J HENLEY III/
Primary Examiner, Art Unit 1629



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

27189 7590 06/18/2025
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B STREET
SUITE 2200
SAN DIEGO, CA 92101

EXAMINER	
HENLEY III, RAYMOND J	
ART UNIT	PAPER NUMBER
1629	

DATE MAILED: 06/18/2025

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	03/28/2025	Reid WALDMAN	135091-0001CT04	3586

TITLE OF INVENTION: COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$516	\$0.00	\$0.00	\$516	09/18/2025

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 40% the amount of undiscounted fees, and micro entity fees are 20% the amount of undiscounted fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via the USPTO patent electronic filing system.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. **Because electronic patent issuance may occur shortly after issue fee payment, any desired continuing application should preferably be filed prior to payment of this issue fee in order not to jeopardize copendency.**

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

27189 7590 06/18/2025

PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B STREET
SUITE 2200
SAN DIEGO, CA 92101

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via the USPTO patent electronic filing system or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	03/28/2025	Reid WALDMAN	135091-0001CT04	3586

TITLE OF INVENTION: COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$516	\$0.00	\$0.00	\$516	09/18/2025

EXAMINER	ART UNIT	CLASS-SUBCLASS
HENLEY III, RAYMOND J	1629	514-275000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

1 _____

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required)

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☐ Electronic Payment via the USPTO patent electronic filing system ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	03/28/2025	Reid WALDMAN	135091-0001CT04	3586
27189	7590	06/18/2025	EXAMINER	
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP			HENLEY III, RAYMOND J	
525 B STREET			ART UNIT	
SUITE 2200			PAPER NUMBER	
SAN DIEGO, CA 92101			1629	

DATE MAILED: 06/18/2025

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013).

<https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>

Routine uses of the information in this record may include disclosure to:

- 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law;
- 2) a federal, state, local, or international agency, in response to its request;
- 3) a contractor of the USPTO having need for the information in order to perform a contract;
- 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record;
- 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record;
- 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations;
- 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals;
- 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c));
- 9) the Office of Personnel Management (OPM) for personnel research purposes; and
- 10) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

Notice of Allowability	Application No. 19/094,716	Applicant(s) WALDMAN, Reid	
	Examiner RAYMOND J HENLEY III	Art Unit 1629	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the papers filed May 27, 2025 and June 04, 2025.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-20. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov**.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1. ☐ Notice of References Cited (PTO-892) | 5. ☐ Examiner's Amendment/Comment |
| 2. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date <u>05/27/2025 & 06/04/2025.</u> | 6. ☐ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material ____. | 7. ☐ Other ____. |
| 4. ☐ Interview Summary (PTO-413),
Paper No./Mail Date. ____. | |

/RAYMOND J HENLEY III/
Primary Examiner, Art Unit 1629

REQUEST FOR REFUND

Reference # (Patent #, Application #, Trademark Serial #, Registration #, etc.)		Title of Invention or Mark Information	
19/094,716		COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL	
Attorney Docket # (if applicable)	Payment Date (mm/dd/yyyy)	Refund Request Amount	
135091-0001CT04	06/27/2025	\$ 200.00	
Refund Option (Select one)			
☒ If approved, issue the refund to the account associated with the original payment.			
☐ If approved, and the original payment was a check, issue the refund to deposit account # _____.			
☐ If approved, and the original payment was a check, issue the refund as a U.S. Treasury check.			
Reason for Refund Request Refund requests must generally be filed within 2 years of payment date (37 CFR 1.26 and 2.209)			
☐ Duplicate Payment ☐ No Fee Due ☐ Office Error ☒ Other: IDS size fee error			
☐ Small Entity Later Established* (Must be filed within 3 months of payment date, 37 CFR 1.28. There is no refund when micro entity is later established.)			
Rationale (Supporting documentation may be submitted with this form)			
The IDS size fee of \$500.00 paid on 6/27/2025 should have \$300.00 since a previous IDS size fee of \$200.00 was paid on 5/27/2025. Therefore, please refund \$200.00 to our Deposit Account No. 502075 associated with this patent application.			

Requester's Information

Company or Firm Name (if applicable)		
Procopio, Cory, Hargreaves & Savitch LLP		
Address Line 1	City	State/Region
525 B Street	San Diego	CA
Address Line 2 (if applicable)	Country	Zip/Postal Code
Suite 2200	US	92101
Email Address (You will receive an acknowledgment of receipt only if you provide a valid email address)		Phone Number
docketing@procopio.com		6192381900
Requester's Name		Registration Number (if applicable)
"Raph" Younghoon Kim		78,715
Signature		Date (mm/dd/yyyy)
/YOUNGHOON KIM/		07/09/2025

Submit online via Patent Center (Patents customers who are registered users only): <https://patentcenter.uspto.gov>, or

Fax to: 571-273-6500, or

Mail to: Mail Stop 16, Director of the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
19/094,716	03/28/2025	Reid WALDMAN	135091-0001CT04

CONFIRMATION NO. 3586

27189
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B STREET
SUITE 2200
SAN DIEGO, CA 92101

PUBLICATION NOTICE



OC00000091323655

Date Mailed: 07/10/2025

Title:COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Publication No.US-2025-0221994-A1

Publication Date:07/10/2025

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be viewed using the USPTO's publicly available Searchable Databases via the Patent Public Search tool at www.uspto.gov. The direct link to access the Patent Public Search tool is currently <https://ppubs.uspto.gov/pubwebapp/static/pages/ppubsbasic.html>.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through Patent Center, the USPTO's electronic patent application filing and management system. The direct link to access this status information is currently <https://patentcenter.uspto.gov/>. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of Patent Center.

Further assistance in electronically accessing the publication, or about Patent Center, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
19/094,716	12/09/2025	12491184	135091-0001CT04	3586

27189 7590 11/26/2025
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B STREET
SUITE 2200
SAN DIEGO, CA 92101

ISSUE NOTIFICATION

The projected patent number and issue date are specified above. The patent will issue electronically. The electronically issued patent is the official patent grant pursuant to 35 U.S.C. § 153. The patent may be accessed on or after the issue date through Patent Center at <https://patentcenter.uspto.gov/>. The patent will be available in both the public and the private sides of Patent Center. Further assistance in electronically accessing the patent, or about Patent Center, is available by calling the Patent Electronic Business Center at 1-888-217-9197.

The USPTO is implementing electronic patent issuance with a transition period, during which period the USPTO will mail a ceremonial paper copy of the electronic patent grant to the correspondence address of record. Additional copies of the patent (i.e., certified and presentation copies) may be ordered for a fee from the USPTO's Certified Copy Center at <https://certifiedcopycenter.uspto.gov/index.html>. The Certified Copy Center may be reached at (800)972-6382.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Center (<https://patentcenter.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Patents Stakeholder Experience (OPSE), Stakeholder Support Division (SSD) at (571)-272-4200.

INVENTOR(s) (Please see PATENT CENTER site <https://patentcenter.uspto.gov> for additional inventors):

Reid WALDMAN, West Hartford, CT;

APPLICANT(s) (Please see PATENT CENTER site <https://patentcenter.uspto.gov> for additional applicants):

Veradermics, Incorporated, New Haven, CT;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit [SelectUSA.gov](https://selectusa.gov).